What is Miroculus?
Founded in 2014 and headquartered in San Francisco, Miroculus is at the forefront of the digital microfluidics revolution. The company specializes in developing sophisticated systems that automate and miniaturize complex genomic protocols, including Next-Generation Sequencing (NGS) library preparation, synthetic biology, cell editing, and combinatorial chemistry. By replacing traditional, labor-intensive manual processes with a compact, user-friendly digital interface, Miroculus is effectively democratizing access to high-throughput genomic research. Its technology is designed to reduce human error, minimize reagent consumption, and accelerate the pace of scientific discovery, positioning the firm as an essential infrastructure provider for modern biotechnology and pharmaceutical enterprises.
How much funding has Miroculus raised?
Miroculus has raised a total of $48.2M across 3 funding rounds:
Angel/Seed
$2.8M
Debt
$350K
Series B
$45M
Angel/Seed (2015): $2.8M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Series B (2021): $45M supported by Cota Capital and Section 32
Key Investors in Miroculus
Cota Capital
Cota Capital is an investment firm that focuses on early-stage technology companies addressing innovative challenges in the enterprise sector. They combine financial investment with deep operational expertise and industry insights to empower founders in building transformative businesses.
Section 32
S32 | Venture Beyond is a venture capital firm that focuses on investing in cutting-edge technology. Their investment strategy targets innovative startups and emerging technologies, supporting visionary entrepreneurs at the forefront of technological advancement.
PPP
Public-Private Partnership
What's next for Miroculus?
With the successful closure of this major strategic investment, Miroculus is well-positioned to accelerate its commercial expansion and deepen its R&D capabilities. The company is expected to leverage this capital to scale its manufacturing capacity, broaden its product portfolio, and expand its footprint in global markets. As the demand for precision medicine and high-throughput genomic analysis continues to surge, Miroculus is poised to capitalize on these industry tailwinds. Future strategic initiatives will likely focus on enhancing the interoperability of its digital microfluidics systems with existing laboratory workflows, thereby cementing its status as a cornerstone technology in the next generation of life sciences research and diagnostic development.
See full Miroculus company page
